Clinical laboratories have started to see therapeutic mAbs in patient sera. This may impact a broad array of activities: t-mAbs may be found as interferences or an incidental finding of iatrogenic monoclonal gammopathy. As targets, the applications of therapeutic drug monitoring for mAbs are growing as is monitoring immune response to therapy and the appearance of anti-drug-antibodies. Notes: RBC, red blood cells; SPE, serum protein electrophoresis; IFE, serum immunofixation electrophoresis.